Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45results about How to "Large index" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
InactiveUS20130137644A1Good curative effectLarge indexNervous disorderAntipyreticHydrophilic polymersPolyethylene glycol
Owner:CELLECTIS SA
Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell
InactiveUS20090186802A1Improve propertiesGood curative effectNervous disorderAntipyreticPolyethylene glycolOligonucleotide
The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.
Owner:CELLECTIS SA
Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
The invention is directed to compounds of formula (I) wherein X is O or NH; R' is a hydrocarbon chain; R<3 >and R<4 >are hydrogen, OH or a monosaccharide; R<5 >is hydrogen or a monosaccharide; Q' is optionally present and may be a C1-10 hydrocarbon; X' is optionally present and may be O, S or NR<8>; and Q<3 >may be a hydrocarbon or hydrogen. The invention is also directed to the use of the compounds for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the compounds of formula (I).
Owner:RES FOUND THE CITY UNIV OF NEW YORK +1
Method for producing high quality optical parts by casting
InactiveUS20060192307A1Quality improvementIncrease costOptical articlesPolymer sciencePolymer thin films
A casting method, rather than injection molding, to produce polymer optical components and systems is provided. The casting process controls shrinkage and stress, thus providing both high bulk uniformity and high quality, accurate surfaces, by incorporating polymer films into the mold. The films may remain incorporated into the part or may optionally be removed from the part after removal from the mold. In addition, the incorporation of separately produced components within the cast part is also provided, eliminating post-casting assembly manufacturing steps.
Owner:GOOGLE LLC
Two-dimensional surface normal slow-light photonic crystal waveguide optical phased array
ActiveUS20120013962A1High thermo-optic coefficientPromote formationCladded optical fibreNanoopticsRefractive indexLaser light
Methods and devices for optical beam steering are disclosed including coupling a laser light into an apparatus comprising a first substrate; an array of air core photonic crystal waveguides; columnar members etched around each air core waveguide; a pair of metal electrodes around the columnar members; a trench around the pair of metal electrodes surrounding each air core photonic crystal waveguide; a second substrate coupled to the first substrate comprising electrical interconnection lines; and a holographic fanout array comprising a third substrate; a photopolymer film coated on the third substrate; a hologram written in the photopolymer film configured to couple the laser light into the third substrate; and an array of holograms recorded in the photopolymer film configured to couple a portion of the laser light into the waveguides; and passing a current through the electrodes to induce a refractive index change in the first substrate to control the phase of the portion of the laser light that passes through each waveguide. Other embodiments are described and claimed.
Owner:OMEGA OPTICS
Liver related disease compositions and methods
InactiveUS20040241657A1Promote digestionMinimize potential damageHydrolasesPeptide/protein ingredientsDisease causeReagent
Composition and methods for use in the therapeutic and preventative treatment, study, diagnosis and prognosis of liver related disease, inflammatory disease and related conditions are disclosed. Also provided are kits and reagents for prognosis and diagnosis of liver related disease, inflammatory disease and related conditions.
Owner:PERLEGEN SCIENCES INC
Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
ActiveUS20040126434A1Potential damageEliminate side effectsBiocideInorganic active ingredientsDentistryHematological malignancy
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also provides methods for making the oral arsenic trioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.
Owner:VERSITECH LTD +1
System and method for non-contact measurement of 3D geometry
InactiveUS20150103358A1Advantageously effectiveRisk minimizationUsing optical meansStereo matchingElectrical polarity
A method for the non-contact measurement of a scene's 3D geometry is based on the concurrent projection of multiple and overlapping light patterns of different wavelengths and / or polarity onto its surfaces. Each location in the overlapping light patterns is encoded (code-word) by the combined arrangements of code elements (code-letters) from one or more of the overlapping patterns. The coded light reflected from the scene is imaged separately for each wavelength and / or polarity by an acquisition unit and code-letters are combined at each pattern location to yield a distinct code-word by a computing unit. Code-words are then identified in the image, stereo-matched, and triangulated, to calculate the range to the projected locations on the scene's surface.
Owner:GALIL SOFT
Red-green-blue polymeric interference film
InactiveUS20050079333A1Improve color uniformityLess abruptMirrorsSynthetic resin layered productsPolarizerPolymer
Multilayer polymeric films and other optical bodies are provided which is useful in making colored mirrors and polarizers. The films are characterized by a change in color as a function of viewing angle.
Owner:3M INNOVATIVE PROPERTIES CO
Data logging system and method thereof for heterogeneous data
ActiveUS20100023545A1Increase scrollingLarge index fileDigital data processing detailsError detection/correctionData viewData recording
The present invention provides a data logging system and a data logging method for heterogeneous data. The record file and the index file according to the present invention are constructed in such a way that the data from the log record corresponding to a given target visual data line are accessible within essentially constant time independent of the position of the visual data line within the data view, the size of the data view, the size of the log record, and the size of the record file. In the present invention, the interpreted data for each log record, occupying zero or at least one of the visual data lines, are represented within the data view continuously side by side. The computer readable medium having recorded thereon a program allowing a computer to execute the data logging method according to the present invention and the computer program product for the same are also provided.
Owner:TIBBO TECH
Polyethylene blends with good contact transparency
InactiveUS7514504B2Good contact transparency and glossHigh environmental stress crack resistanceLow-density polyethyleneLinear low-density polyethylene
Owner:TOTAL RES & TECH FELUY
Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
ActiveUS20090123510A1Potential damageEliminate side effectsBiocideSugar derivativesProsthesisAdenosine a
The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A2A receptor, in particular, an agonist of an adenosine A2A receptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine A2A agonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an A2A agonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.
Owner:NEW YORK UNIV
Polyethylene blends with good contact transparency
InactiveUS20050222338A1Good transparencyHigh stress crack resistanceHigh-density polyethylenePolymer blend
This invention discloses the production and use of a polyethylene composition comprising a metallocene-produced linear low density polyethylene and a multi modal high density polyethylene prepared from either a Ziegler-Natta or a metallocene catalyst system. The resulting polyethylene composition is suitable for preparing articles having improved environmental stress crack resistance, rigidity, contact transparency, gloss as well as good processing capabilities.
Owner:TOTAL RES & TECH FELUY
Derivatives of isoindigo, indigo and indirubin and methods of treating cancer
InactiveUS6933315B2Minor side effectsMinimal toxicityBiocideSugar derivativesMedicineBioavailability
A compound called NATURA, which is a derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirubin derivatives are designed such that the bioactivity or bioavailability of the compound is increased. Methods of synthesizing these derivatives is also taught. In addition, pharmaceutical compositions that include a therapeutically effective amount of at least one of these derivatives and a pharmaceutically acceptable carrier. A method for the use of these pharmaceutical compositions and compounds is taught, wherein a therapeutically effective amount is administered to an animal having solid tumor cancer. The pharmaceutical composition or compound can be re-administered to the animal until a desired treatment or result is accomplished.
Owner:NATROGEN THERAPEUTICS INT
Anti-mesothelin antibodies and uses thereof
ActiveUS20110027268A1Large indexBacteriaImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesAnti-Mesothelin Antibody
The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Owner:BAYER INTELLECTUAL PROPERTY GMBH
Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
InactiveUS20090214590A1Minimal toxicityMinimize potential damageSsRNA viruses negative-senseViral antigen ingredientsAdjuvantCytokine
The present invention provides novel virus vaccines with augmented, e.g., enhanced and / or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus vaccine, thereby augmenting, e.g., enhancing or extending immune response to the virus when administered to a subject.
Owner:WAYNE STATE UNIV
Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury
The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4′,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.
Owner:US DEPT OF HEALTH & HUMAN SERVICES +2
Two-dimensional surface normal slow-light photonic crystal waveguide optical phased array
ActiveUS8200055B2High thermo-optic coefficientPromote formationCladded optical fibreNanoopticsRefractive indexLaser light
Methods and devices for optical beam steering are disclosed including coupling a laser light into an apparatus comprising a first substrate; an array of air core photonic crystal waveguides; columnar members etched around each air core waveguide; a pair of metal electrodes around the columnar members; a trench around the pair of metal electrodes surrounding each air core photonic crystal waveguide; a second substrate coupled to the first substrate comprising electrical interconnection lines; and a holographic fanout array comprising a third substrate; a photopolymer film coated on the third substrate; a hologram written in the photopolymer film configured to couple the laser light into the third substrate; and an array of holograms recorded in the photopolymer film configured to couple a portion of the laser light into the waveguides; and passing a current through the electrodes to induce a refractive index change in the first substrate to control the phase of the portion of the laser light that passes through each waveguide. Other embodiments are described and claimed.
Owner:OMEGA OPTICS
Macular degeneration diagnostics and therapeutics
InactiveUS6417342B1Potential damageEliminate side effectsSugar derivativesBacteriaGenes mutationCell biology
Therapeutics and diagnostics based on the identification of genetic mutations, which cause Macular Degeneration (MD) is disclosed.
Owner:IOWA UNIV OF RES FOUND THE
Optical communication system
InactiveUS6965739B2Improve noise characteristicsReduce in quantityTransmission control/equlisationFrequency-division multiplex detailsIntermediate frequencyCarrier signal
An optical communication system for optically transmitting transmission data from a transmitting station to a transmitting device includes an adder for adding an intermediate frequency subcarrier signal modulated with data to be transmitted to a pilot carrier signal as a sinusoidal wave, and an electro-optical converter for electro-optically converting the above sum signal to an optical signal by directly modulating a semiconductor laser element having a resonant frequency fr in accordance with the sum signal and transmitting the signal to an optical fiber for a down link. The frequency fIF of the intermediate frequency subcarrier signal and the frequency fLO of the pilot carrier signal satisfyfLO−fIF≧1[GHz],2×fIF<fLO<(⅔)×fr,fIF<1[GHz], and2 [GHz]<fLO.
Owner:KK TOSHIBA
CD2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
InactiveUS20150165018A1Potential damageEliminate side effectsViral antigen ingredientsInactivation/attenuationHylochoerus meinertzhageniDomestic pig
The present invention is directed to a preferably live attenuated or subsequently inactivated African swine fever virus (ASFV), comprising a non-functional genomic CD2 gene, wherein such ASFV is non deficient in its replication, as well as to corresponding compositions or immunogenic compositions or vaccines, methods of production and uses for treating and / or preventing African swine fever in mammals, preferably of the family Suidae, for instance pigs, more preferably domestic pigs (Sus scrofa domesticus), wild pigs (Sus scrofa scrofa), warthogs (Potamochoerus porcus), bushpigs (Potamochoerus larvatus), giant forest hogs (Hylochoerus meinertzhageni) as well as feral pigs.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell
InactiveUS20120010124A9Good curative effectLarge indexPeptide/protein ingredientsAntipyreticHydrophilic polymersPolyethylene glycol
Owner:CELLECTIS SA
Nucleic acid triggered catalytic drug and probe release
InactiveUS7445891B2Potential damageEliminate side effectsBiocideSugar derivativesNucleic acid sequencingDisease specific
The present invention provides methods and combinations of compositions for the modulation of diseases caused by a subject possessing a disease-specific nucleic acid sequence. Included are methods for the treatment, prevention and / or inhibition of the diseases by administering a combination of a prodrug component, drug and catalytic component such that the drug is catalytically released when contacting the combination to the disease-specific nucleic acid sequence.
Owner:TAYLOR JOHN STEPHEN
Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
InactiveUS20060240033A1Enhance antigen-specific immune responseImproving immunogenicityViral antigen ingredientsWhole-cell/virus/DNA/RNA ingredientsAdjuvantAutoimmune condition
The present invention is directed to the discovery that allogenic or syngenic adjuvant stimulation can cause local inflammation which increases the antigen presentation capability of cells in the vicinity of adjuvant stimulation. By discovering this phenomenon, the present invention provides a novel method for augmenting the immunogencity of an antigen by conjointly administering an allogenic or syngenic MHC molecule (as a universal adjuvant) to trigger a local inflammatory reaction to enhance antigen presentation at the site of delivery.
Owner:NEW YORK UNIV
Data logging system and method thereof for heterogeneous data
ActiveUS8024297B2Efficient mechanismImprove viewing effectDigital data processing detailsError detection/correctionData viewData recording
The present invention provides a data logging system and a data logging method for heterogeneous data. The record file and the index file according to the present invention are constructed in such a way that the data from the log record corresponding to a given target visual data line are accessible within essentially constant time independent of the position of the visual data line within the data view, the size of the data view, the size of the log record, and the size of the record file. In the present invention, the interpreted data for each log record, occupying zero or at least one of the visual data lines, are represented within the data view continuously side by side. The computer readable medium having recorded thereon a program allowing a computer to execute the data logging method according to the present invention and the computer program product for the same are also provided.
Owner:TIBBO TECH
Method for treating tumor using a combination of energy and antibody conjugated toxin
InactiveUS20020192221A1Stop tumor growthPotential damageUltrasound therapyElectrotherapyAntiendomysial antibodiesTumor targeting
The present invention relates to a method for treating a tumor that contains fibrin. The method comprises utilizing an energy from an energy source to destroy at least a portion of (i) a fibrin contained in the tumor or (ii) fibrin surrounded tumor. The energy may also cause necrosis of tumor cells that are adjacent to the fibrin. The method further include the use of a tumor-targeting monoclonal antibody conjugated to a toxin which is administered to the subject. The present invention also relates to a method for removing and killing fibrin-associated tumor cells from a mixed cell population, which method includes the step of delivering an energy from an energy source to the fibrin-associated tumor cells and killing the tumor cells with a tumor-targeting monoclonal antibody conjugated to a toxin.
Owner:AMERICAN BIOGENETIC SCI
Methods and compositions for treating osteoarthritis and promoting cartilage formation
ActiveUS20180036238A1Minimize potential damageEliminate side effectsInorganic non-active ingredientsSkeletal disorderDipyridamoleTicagrelor
The invention provides methods and compositions for treating or inhibiting the development of osteoarthritis in a subject having osteoarthritis or at risk for developing osteoarthritis and for stimulating or increasing cartilage production or formation in a subject. The methods feature administering to the subject a therapeutically effective amount of a composition comprising one or more agent from among adenosine, an adenosine receptor agonist, and an agent that upregulates or increases the amount of or the biological activity of adenosine, or an analog or derivative thereof. The adenosine receptor may be an A1, A2A, A2B and A3 adenosine receptor. The agent that upregulates or increases the amount of or the biological activity of adenosine may be dipyridamole or ticagrelor. The composition may be administered via intraarticular injection such as injection into the synovial fluid of a joint. The composition may be effective to reduce or inhibit degeneration or damage to cartilage or to stimulate or increase cartilage production or formation. The composition may be a liposomal composition or contain a liposome.
Owner:NEW YORK UNIV
Illumination apparatus with gradually changeable color temperatures
InactiveUS20140265926A1Large indexSimulating variationElectrical apparatusElectroluminescent light sourcesColor rendering indexColor temperature
The present invention provides an illumination apparatus with gradually changeable color temperatures; the apparatus includes an illumination module and a control module. The illumination module is utilized to generate an illuminating light which has a plurality of different color temperatures. The control module is utilized to control a color temperature variation of the illuminating light so that a color difference in Duv corresponding to the variation of the illuminating light is less than 0.006 under the color temperature variation. Moreover, all color rendering indices of the illuminating light corresponding to the different color temperatures are larger than 90, thereby completely simulating the variation of sun.
Owner:NAT TAIWAN UNIV OF SCI & TECH
Compositions and methods of using a soluble TNF-alpha receptor modified for increased half-life
InactiveUS20180028612A1Effective preventionEffective treatmentOrganic active ingredientsPeptide/protein ingredientsDiabetic retinopathyEnprofylline
Methods and pharmaceutical compositions for preventing and / or treating acute and chronic inflammation and autoimmune diseases are provided herein. Tumor necrosis factor-α (TNFα) promotes an inflammatory response, which causes clinical problems associated with inflammation and autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. TNFα is also implicated in promoting pathogenesis of diabetic retinopathy leading to loss of retinal microvascular cells. Methods herein contain the step of administering a prophylactic and / or therapeutic formulation of a pharmaceutical composition containing a recombinant soluble human TNF receptor or portions thereof which are TNFα inhibitors. These pharmaceutic compositions have been modified by conjugating natural amino acids such as proline and alanine, and / or serine (PA / S) via PASylation® to create a linear polypeptide that possesses fewer of the processing, preparation, formulation, cost, and other long-term issues of administering PEGylated drugs.
Owner:DNX BIOTECH LLC
Compositions and methods for treating diseases
ActiveUS20170028002A1Increasing WT GAA activityPotential damageNervous disorderMetabolism disorderDiseaseTarget expression
The present invention provides compositions and methods of use pertaining to rAAV-mediated delivery of therapeutically effective molecules for treatment of diseases such as Pompe disease. These compositions in combination with various routes and methods of administration result in targeted expression of therapeutic molecules in specific organs, tissues and cells.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com